Skip to Main Content

Paper Details

Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic Cancer.
Clin Cancer Res
7
2023
BRAF, BRAF in-frame deletions, BRAF mutations, CTNNB1, GNAS, KRAS, KRAS WT, KRAS WT tumor, KRAS wild-type (WT) pancreatic cancer, MAPK, MEK, MYC, PDAC, PIK3CA, RAF, ROS1, ROS1 fusion, SMAD4, exocrine pancreatic cancer, in, pancreatic cancer, pancreatic ductal adenocarcinomas, patient, patient-derived organoid models, patients, receptor tyrosine kinase fusions, tyrosine
Author NameAffiliation
Matthew B YurgelunDana-Farber Cancer Institute
Matthew B YurgelunBrigham and Women's Hospital
Matthew B YurgelunHarvard Medical School
Jason L HornickBrigham and Women's Hospital
Andrew D CherniackDana-Farber Cancer Institute
Andrew D CherniackThe Broad Institute of Harvard and MIT
Andrew D CherniackHarvard Medical School
Andrew D CherniackDana-Farber Cancer Institute
Andrew D CherniackHarvard Medical School
Andrew D CherniackThe Broad Institute of Harvard and MIT
Matthew MeyersonDana-Farber Cancer Institute
Matthew MeyersonHarvard Medical School
Matthew MeyersonThe Broad Institute of Harvard and MIT
Matthew MeyersonDana-Farber Cancer Institute
Matthew MeyersonHarvard Medical School
Matthew MeyersonThe Broad Institute of Harvard and MIT
  • 1 - 16

Datasets

Release 1.2